# The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

> **NCT01518985** · PHASE1 · COMPLETED · sponsor: **Stealth BioTherapeutics Inc.** · enrollment: 6 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Bendavia
- **DRUG:** Sterile saline (0.9%)
- **OTHER:** Cigarette smoking

## Key facts

- **NCT ID:** NCT01518985
- **Lead sponsor:** Stealth BioTherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2012-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518985, "The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01518985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*